Azienda Ulss 6 Euganea
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Azienda Ulss 6 Euganea in Padua, clinical research in Cardiovascular Diseases focuses on major conditions such as hypertension, peripheral arterial disease, established cardiovascular disease, and primary prevention of atherosclerotic cardiovascular disease. These studies are designed to test new treatment approaches and assess whether they can better lower the risk of serious heart and vascular events.
- Evaluating therapies intended to reduce major cardiovascular events in people at elevated risk
- Studying treatment options for hypertension that remains difficult to control
- Assessing strategies to prevent complications in peripheral arterial disease
The research reflects a strong interest in prevention, risk reduction, and improving long-term outcomes for patients with significant cardiovascular conditions.
Neoplasms
The site also conducts oncology research within Neoplasms, with studies centered on breast cancer and multiple myeloma. In this setting, investigators are exploring whether newer treatment strategies can improve survival outcomes and support patients who need alternatives to standard care.
- Testing adjuvant treatment approaches for high-risk triple negative breast cancer
- Comparing treatment strategies for multiple myeloma in patients not eligible for autologous stem cell transplant
- Evaluating whether new therapies can improve disease control and reduce recurrence
This oncology portfolio highlights research aimed at improving effectiveness, extending remission, and addressing unmet needs in aggressive or hard-to-treat cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ulss 6 Euganea
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Low-Dose Colchicine in Reducing Cardiovascular Events in Patients with Peripheral Arterial Disease: A Randomized Controlled Trial | Hamilton Health Sciences Corporation | Phase III | Recruiting | Jun 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Avelumab | 1 | Unknown | 2016-06-16 | 2016-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.